Status:
COMPLETED
Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Erythemato-telangiectatic Rosacea
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study will evaluate the safety, tolerability and efficacy of BFH772 after 12 weeks of treatment as compared to an active control and vehicle in patients with erythemato-telangiectatic rosacea.
Eligibility Criteria
Inclusion
- Have persistent facial erythema on the cheeks of at least moderate severity.
- Women must not be able to bear children
Exclusion
- Have more than 12 inflammatory lesions on the face
- Previous treatment of facial skin with lasers or electrocauterisation within 2 months prior to entering the study
- Have facial hair that makes it difficult to evaluate rosacea on the face Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT01449591
Start Date
September 1 2011
End Date
February 1 2012
Last Update
February 21 2021
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Hot Springs, Arkansas, United States
2
Novartis Investigative Site
Ann Arbor, Michigan, United States
3
Novartis Investigative Site
Paramus, New Jersey, United States
4
Novartis Investigative Site
Portland, Oregon, United States